Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing
Although clinical trials in the cell and gene therapy space have skyrocketed, there’s a significant shortfall in the skilled talent required to execute on the exponential potential of cell and gene therapies. Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury discuss the biotherapeutic process and manufacturing talent gap, and propose a multipronged approach to addressing the problem through internal innovation and the external influence of academia and industry associations.
Breaking The Bottleneck For Cell And Gene Therapy Studies: Strategies For Creating Clinical Enthusiasm And Selecting Sites
A big bottleneck in the evolving field of cell and gene therapy is identifying sites with the capability and capacity to conduct these resource-intensive studies. Gene and cell therapy developers need to create clinical interest to find champions at investigative sites and differentiate their products and clinical trials to keep development moving forward. Precision’s Megan Liles explores strategies for building clinical enthusiasm and selecting the right sites for gene and cell therapy trials.
Precision Medicine Group Secures Major Investment from Blackstone
On-demand Webinar: 2020 Social Determinants of Health Series–Assessing and Addressing Social Determinants of Health During a Pandemic
This second webinar in our SDOH series will feature KOLs emphasizing applied learnings in the SDOH and population health fields. The session will address collaborative patient engagement: how styles of communication, analytics, telemedicine and PHM are tackling social risks and engaging patients in the pandemic/infodemic era.
On-demand Webinar: Considerations for Internal Versus External Manufacturing for Developing Cell and Gene Therapies
Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?